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Abstract
Background: In advanced malignant disease, cachexia and
muscle wasting appear to be among the most common
manifestations. This phenomenon is partially related with a
decreased muscle regeneration capacity, as previously
described in our laboratory.
Methods and results: Rats bearing the Yoshida AH-130
ascites hepatoma were used in the experiments. The animals
experienced a marked weight loss with decreases in skeletal
muscle weights (13% gastrocnemius, 18% extensor digito-
rum longus, and 12% tibialis muscles). Muscle gene
expression was measured using real-time polymerase chain
reaction. Skeletal muscle from cachectic tumour-bearing rats
is associated with a decreased expression of genes involved
in regeneration such as Pax-7 (39%), myogenin (24%), and
MyoD (17%). mRNA levels of Sirt1 increased (91%) in
cachectic skeletal muscle. The Sirt1 gene has been shown to
be associated with changes in muscle myoblast differentia-
tion. Treatment of the tumour-bearing animals with formo-
terol—a beta2-agonist—normalizes the expression of genes
involved in regeneration (i.e., increase of Pax7 (139%)), at
the same time as it does with that of Sirt1 (42% decrease).
Conclusions: It is suggested that the lack of muscle
regeneration observed during muscle wasting in tumour-
bearing animals is linked to the action of Sirt-1, possibly
via PGC-1α. These factors may constitute possible targets
of pharmacological treatment against muscle loss, thus
potentially contributing to the understanding and mitigation
of muscle atrophy associated with disease.
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1 Introduction
In advanced malignant diseases, cachexia appears to be one
of the most common systemic manifestations. The presence
of cachexia always implies a poor prognosis, having a great
impact on the patients' quality of life and survival [1].
Several important molecular mechanisms have been shown
to be involved in the increased muscle catabolism observed
in cancer-induced cachexia, such as greater ubiquitin–
proteasome-dependent proteolysis, apoptosis, and activa-
tion of uncoupling proteins [2–5]. Interaction of these
mechanisms leads to muscle mass loss by promoting
protein and DNA breakdown and energy inefficiency.
The sirtuin family of proteins possesses NAD
+-depen-
dent deacetylase activity and/or ADP ribosyltransferase
activity. The seven mammalian sirtuins (Sirt1–7) are
localized differentially within the cell and have a variety
of functions [6]. Sirt1 is the most extensively studied
member of the family and regulates diverse biological
processes ranging from cell proliferation, differentiation,
apoptosis, and metabolism [7]. Sirt3—a sirtuin present in
the mitochondria [8] which seems to be able to control
thermogenesis—has been linked to longevity in men, and
aberrant expression of this sirtuin correlates with node-
positive breast cancer in clinical biopsies from women [9],
suggesting that Sirt3 serves as an important diagnostic and
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affecting men and women in unique ways. Both Sirt1 and
3 seem to be regulated both by diet [10, 11] and exercise
[10].
β2-Adrenergic agonists are potent muscle growth pro-
moters in many animal species [12, 13], resulting in skeletal
muscle hypertrophy [14–17]. Formoterol is one of these
compounds with important anti-cachectic effects in animal
models. The mechanism of action of this drug is based
on its ability to prevent muscle wasting by inhibiting
proteolysis in skeletal muscle. Thus, this β2-agonist is
able to decrease the activation of the ubiquitin-dependent
proteolytic system, the main mechanism activated in
muscle-wasting conditions [18]. Interestingly, in addition
to its anti-proteolytic effects, formoterol also decreases
muscle apoptosis in muscle-wasting animals [18].
After an injury within the muscle, there is an effective
restoration of its structure and function [19]. This is
possible due to existence of a population of mononuclear-
acquired myogenic precursors, known as satellite cells [20].
These cells in adult muscle are in quiescent phase [21].
With the appropriate environmental signals, there is an
activation of them and they become precursors for the
formation of new muscles during growth or to repair
muscle after an injury [22]. β2-Adrenergic agonists increase
the ability of skeletal muscle repair after injury [23–29].
Bearing all this in mind, the objective of the present
investigation was to measure the levels of Sirt1 and 3
gene expression in skeletal muscle of cachectic tumour-
bearing animals and to relate them with the alterations
found in skeletal muscle during cachexia. In addition, the
effects of formoterol treatment (a highly effective
anabolic treatment for cancer cachexia [18]) on sirtuin
content were studied.
2 Material and methods
2.1 Animals
Male Wistar rats (Interfauna, Barcelona, Spain) of 5 weeks
of age were used in the different experiments. The animals
were maintained at 22±2°C with a regular light–dark cycle
(light on from 08:00 A.M. to 08:00 P.M.) and had free access
to food and water. The food intake was measured daily. All
animal manipulations were made in accordance with the
European Community guidelines for the use of laboratory
animals.
2.2 Tumour inoculation and formoterol treatment
Rats were divided into two groups, namely controls (n=14)
and tumour hosts (n=14). The latter received an intraper-
itoneal (i.p.) inoculum of 10
8 AH-130 Yoshida ascites
hepatoma cells obtained from exponential tumours [30].
Both groups were further divided into treated (n=7) and
untreated (n=7), the former one being administered a daily
subcutaneous dose of formoterol (0.3 mg/kg body weight,
Table 1 Muscle weights and protein content in rats bearing the Yoshida AH-130 ascites hepatoma
C C+F TB TB+F ANOVA
AB
Food intake 106±2 112±3 78±4 83±2 0.0000 NS
Tumour content ––3,648±150 3,750±180 NS
Muscle weights
Gastrocnemius 637±20 710±23 553±11 627±10 0.0000 0.0001
Tibialis 214±6 238±4 188±3 206±5 0.0000 0.0001
Soleus 44±1 48±1 42±1 45±2 NS 0.0291
EDL 51±2 58±1 42±2 47±1 0.0000 0.0007
GSN
Protein content 212±10 290±20 173±20 271±20 0.1570 0.0004
Results are mean ± standard error of the mean for seven animals
Food intake is expressed in grams per 100 g initial body weight and refers to the ingestion during the period of the experiment prior to sacrifice
which took place 7 days after tumour inoculation
Tissue weights are expressed as milligrams per 100 g of initial body weight
Tumour cell content is expressed in millions of cells. The protein content is expressed in milligrams of protein per gram GSN
Statistical significance of the results by two-way ANOVA
EDL extensor digitorum longus, C control animals, T tumour-bearing rats, F formoterol-treated animals, GSN gastrocnemius, ANOVA analysis of
variance, NS non-significant differences, A tumour effect, B treatment effect
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corresponding volume of solvent. On day 7 after tumour
transplantation, the animals were weighed and anesthetized
with an i.p. injection of ketamine/xylazine mixture (3:1;
Imalgene
® and Rompun
®, respectively). The tumour was
harvested from the peritoneal cavity and its volume and cell
content evaluated. Tissues were rapidly excised, weighed,
and frozen in liquid nitrogen.
2.3 RNA isolation
Total RNA from gastrocnemius muscle was extracted by
TriPure
TM kit (Roche, Barcelona, Spain), a commercial
modification of the acid guanidinium isothiocyanate/
phenol/chloroform method [31].
2.4 Real-time polymerase chain reaction
First-strand cDNA was synthesized from total RNA with
oligo dT15 primers and random primers pdN6 by using a
cDNA synthesis kit (Transcriptor Reverse Transcriptase,
Roche, Barcelona, Spain). Analysis of mRNA levels for
Sirt1, Sirt3, Pax7, MyoD, myogenin, and 18S was
performed with primers designed to detect these products:
Sirt1: UP—AGCTGGGGTTTCTGTTTCCTGTGG, DO—
TCGAACATGGCTTGAGGATCTGGGA; Sirt3: UP—
CGGCTTTGGATGTGGAGGACAC, DO—CCTG
GGGATCTGAAGTCTGGGATAC; Pax7: UP—
GGAAAACCAGTGTGCCATCT, DO— CC
TTGTCTTTGGCACCATTT; MyoD: UP—CGACT
GCTTTCTTCACCACA, DO—CTCAACCCAAGCCT
GAAGAG; myogenin: UP—GTCTTTTCCGACCT
GATGGA, DO—GTCCCCAGTCCCTTCTCTTC, and
18S: UP—CGCAGAATTCCCACTCCCGACCC, DO—
CCCAAGCTCCAACTACGAGC. To avoid the detection
of possible contamination by genomic DNA, primers were
designed in different exons. The real-time polymerase chain
reaction was performed using a commercial kit (Light-
Cycler
TM 480 SYBR Green I Master, Roche, Barcelona,
Spain). The relative amount of all mRNA was calculated
using comparative CT method. 18S mRNA was used as the
invariant control for all studies.
2.5 Protein content
Protein concentration wasdetermined accordingto themethod
of bicinchoninic acid (Pierce, Spain) and was expressed in
milligrams of protein per gram of gastrocnemius muscle.
2.6 Western blot
Gastrocnemius muscle was homogenized in 10 mmol/L 4-(2-
hydroxyethyl)-1-piperazineethanesulphonic acid (pH 7.5),
10 mmol/L MgCl2, 5 mmol/L KCl, 0.1 mmol/L EDTA,
0.1% Triton X-100, 1 mmol/L dithiothreitol (DTT) and
5 μL/mL of buffer of a protease inhibitor cocktail (Sigma,
Spain). Tissue homogenates were then centrifuged at
7,000 rpm for 5 min at 4°C, and the supernatants were
collected. Protein concentrations were determined according
to the method of bicinchoninic acid (Pierce, Spain). Equal
amounts of protein (50 or 100 μg) were heat-denatured in
sample loading buffer (50 mmol/L Tris–HCl (pH 6.8),
100 mmol/L DTT, 2% sodium dodecyl sulfate (SDS), 0.1%
bromophenol blue, 10% glycerol), resolved by SDS–poly-
acrylamide gel electrophoresis (10% polyacrylamide, 0.1%
SDS) and transferred to Immobilon membranes (Immobilon
polyvinylidene difluoride, Millipore). The filters were
blocked with 5% phosphate-buffered saline with non-fat dry
milk and then incubated with polyclonal antibody anti-cyclin
D1 (Santa Cruz Biotechnology). Polyclonal antibody anti-
Fig. 1 Sirtuin 1 and 3 mRNA content in gastrocnemius muscles from
tumour-bearing rats. Results are mean ± standard error of the mean for
seven animals. The results of gene expression are expressed as a
percentage of controls (arbitrary units). C control animals, T tumour-
bearing rats, F formoterol-treated animals. Statistical significance of
the results by one-way ANOVA, between groups (p<0.001), and
statistically significant difference by post hoc Duncan test. Different
superscripts indicate significant differences between groups
J Cachexia Sarcopenia Muscle (2011) 2:57–62 59GAPDH (Sigma, Spain) was used as the invariant control.
Goat anti-rabbit horseradish peroxidase conjugate (Bio-Rad)
was used as secondary antibody. The membrane-bound
immune complexes were detected by an enhanced chemilu-
minescence system (EZ-ECL, Amersham Biosciences).
2.7 Statistical analysis
Statistical analysis of the data was performed by means of
one- and two-way analysis of variance (ANOVA).
3 Results
As can be seen in Table 1, the implantation of the Yoshida
AH-130 ascites hepatoma caused important decreases in the
weight of gastrocnemius (13%), extensor digitorum longus
(18%), and tibialis muscles (12%). These changes were
accompanied by significant decrease in protein content
(Table 1). Formoterol treatment was able to significantly
increase muscle weight and protein content (Table 1). These
data agree withpreviousresults fromour own laboratory[18].
Figure 1 shows the Sirt1 and 3 mRNA content in skeletal
muscle. As can be seen, tumour burden resulted in a
significant increase in Sirt1 gene expression (91%) in
gastrocnemius muscles, in relation with the non-tumour-
bearing control animals. Interestingly, administration of
formoterol results in a decrease in the levels of Sirt1 mRNA
in the tumour-bearing animals without affecting the levels
found in the control rats (Fig. 1). Conversely, no changes
were observed in the mRNA levels of Sirt3 in any of the
experimental groups studied (Fig. 1).
Fig. 2 Hypothetical involvement
of Sirt1 in muscle wasting.
Formoterol treatment is able to
partially block not only the
changesinproteinandaminoacid
(AA)m e t a b o l i s mb u ta l s oi n
apoptosis and muscle regenera-
tion, possibly via Sirt1. BCAA
branched chain amino acids
Table 2 Pax7, myogenin, and MyoD mRNA content in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma
C C+F TB TB+F ANOVA
AB
mRNA
Pax7 100±10 137±16 62±11 143±19 NS 0.0252
MyoD 100±5 97±12 82±5 79±8 0.0456 NS
Myogenin 100±6 89±14 75±9 48±5 0.0322 0.0432
Protein
Cyclin D 100±7 58±13 76±6 50±5 0.0467 0.0187
For more details, see the “Material and methods” section
Results are mean ± standard error of the mean for seven animals
The results of gene expression are expressed as a percentage of controls. Statistical significance of the results by two-way ANOVA
C control animals, T tumour-bearing rats, F formoterol-treated animals, NS non-significant differences, A tumour effect, B treatment effect
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myoblast differentiation [32, 33], we decided to investigate
the levels of differentiation markers in skeletal muscle from
tumour-bearing rats. As can be seen in Table 2, tumour-
bearing rats showed decreased mRNA content for Pax7
(39%), myogenin (24%), and MyoD (17%). Formoterol
treatment increased Pax7 gene expression (139%) while
reducing that of myogenin (53%) and decreased the protein
levels of cyclin D (38%).
4 Discussion
This is the first report on Sirt1 gene expression in skeletal
muscle in catabolic conditions. Caloric restriction has been
reported to increase Sirt1 content in skeletal muscle [11];
this could be relevant since tumour-bearing rats suffer from
anorexia (Table 1). Formoterol does not affect food intake
(Table 1); therefore, the increase in Sirt1 in muscle is not
likely to have been triggered by caloric restriction in this
experimental model. Other factors of inflammatory origin
may be involved. From this point of view, TNF-α—a
cytokine which is elevated in the tumour model chosen and
that has been involucrated in muscle wasting [34–36]—has
been shown to be responsible for increasing Sirt1 in
vascular smooth muscle cells [37]. However, during
sarcopenia, an increase in Sirt1 satellite cell content has
been described [38]. Conversely, no changes were observed
in the mRNA levels of Sirt3 in any of the experimental
groups studied. This observation is in contrast with that of
Alamdari et al. [39], showing an upregulation of Sirt3 in
skeletal muscle during sepsis, a catabolic condition also
characterized by intense muscle wasting.
Since Sirt1 has been associated with changes in muscle
myoblast differentiation [32, 33], we decided to investigate
the levels of differentiation markers in skeletal muscle from
tumour-bearing rats. Different molecules involved in the
process of muscle regeneration and in the regulation of
satellite cells, such as Pax7, MyoD, and myogenin [20], are
known (Fig. 2). In adult skeletal muscle, Pax7 is expressed
in the majority of quiescent satellite cells. These cells, when
activated, co-express Pax7 and MyoD [25, 40, 41]. When
they proliferate, the levels of Pax7 decrease and other
molecules involved in differentiation (such as myogenin)
increase their expression. There is a part of the proliferating
population that maintains the levels of Pax7, but not of
MyoD, which returns to their state of quiescence [40–42].
The mRNA content decrease in tumour-bearing animals for
Pax7, myogenin, and MyoD suggests a decrease in the rate
of myoblast differentiation. Indeed Pax7 is a marker of
satellite cell differentiation [29]. Interestingly, formoterol
treatment increased Pax7 gene expression and increased
myogenin gene expression, this clearly indicating that the
beta agonist is able to activate satellite cell differentiation
(Fig. 2). This is supported by the decrease in the protein
levels of cyclin D—a marker of cell proliferation.
Sirt1 controls the transcription of the peroxisome
proliferator-activated receptor (PPAR)-gamma co-activator
1alpha (PGC-1α) in skeletal muscle [43] (Fig. 2). In fact,
tumour burden resulted in significant increases in PGC-1α
in cachectic muscles [44]. Interestingly, formoterol treat-
ment significantly decreased the levels of the co-activator
both in control and tumour-bearing animals [44]. The
results presented here indicate that the lack of muscle
regeneration associated with muscle wasting during cancer
[29] is likely to be associated with changes in Sirt1 content
in skeletal muscle. This opens a new perspective in
understanding muscle wasting associated with cancer
cachexia and may lead to new approaches in the design of
therapeutic strategies. In addition, Sirt1 may play a key
modulatory role in animal fat deposition—it promotes fat
mobilization by repressing PPAR-gamma [32] and muscle
development, therefore contributing to the inter-organic
metabolic cross-talk, as previously reported by our group
[45].
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